RDCRN Web Site | Open Studies

 

 


<< Conference Home
----------------------
Background and Goals

 

----------------------
Program Agenda
Speaker Roster


----------------------
Travel Awards
Abstract Submission and Poster Requirements


Contact Information

RDCRN Web Site

Background & Goals

There are more than 6,000 diseases classified as “rare” (defined as having a prevalence in the United States of <200,000 persons).  While individually these entities are uncommon, as a group they are an important cause of chronic illness, disability and premature death in both children and adults.  They take a disproportionate share of our health care dollars because of their complexity and the expense of, in most cases, inadequate therapy.  Despite their rarity, many fundamental advances in medicine have come from the study of rare diseases and these have benefited common diseases.  As an example, the study of the human genome began with identification of rare diseases (muscular dystrophy being the first) and epigenetics was first identified in rare disorders.  Both because of currently inadequate therapy and the potential to assist common as well as rare disorders, the conduct of clinical research in rare diseases is essential.

In order to assure the future of this research, the training of the next generation of investigators in this field is important.  The NIH Rare Diseases Clinical Research Network (RDCRN, www.RareDiseasesNetwork.org) is the ideal group to sponsor a conference addressing rare disease research methodology that would supplement general training in clinical research and help attract trainees and junior faculty into this important field.

The RDCRN was funded by the NIH Offices of Rare Disease Research in 2003 in order to support regional centers of excellence for clinical research into diagnosis, prevention, control, and treatment methods for rare diseases.  The RDCRN consists of ten (10) Rare Diseases Clinical Research Network Consortia, in addition to a Data Technology and Training Center, and studies approximately 50 rare diseases in over 70 academic institutions from around the country with over 200 investigators.  Each consortium is performing longitudinal natural history studies, conducting clinical trials of new medications, often in collaboration with industry sponsors, collaborating with patient advocacy groups, and training future leaders in the field.  Currently there are over 20 clinical studies actively enrolling patients.

Clinical research in rare diseases presents a number of challenges and unique issues that are not usually considered in the training of clinical investigators through existing training programs.  Goals of the conference include:

  • Direct instruction of trainees and new investigators in rare disease research methodology
  • Development of a reusable curriculum/syllabus on rare disease research methodology
  • Stimulation of ideas regarding the unique issues facing investigators engaged in the study of rare diseases